Details for Patent: 11,590,207
✉ Email this page to a colleague
Which drugs does patent 11,590,207 protect, and when does it expire?
Patent 11,590,207 protects YORVIPATH and is included in one NDA.
This patent has thirty-four patent family members in twenty-five countries.
Drugs Protected by US Patent 11,590,207
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-001 | Aug 9, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS | ⤷ Subscribe | ||||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-002 | Aug 9, 2024 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS | ⤷ Subscribe | ||||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-003 | Aug 9, 2024 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,590,207
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017336249 | ⤷ Subscribe | |||
| Brazil | 112019005533 | ⤷ Subscribe | |||
| Canada | 3037442 | ⤷ Subscribe | |||
| China | 109789189 | ⤷ Subscribe | |||
| China | 117838873 | ⤷ Subscribe | |||
| Denmark | 3518960 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
